Filgrastim improves survival in lethally irradiated nonhuman primates

Ann M. Farese, Melanie V. Cohen, Barry Katz, Cassandra P. Smith, Allison Gibbs, Daniel M. Cohen, Thomas J. MacVittie

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Treatment of individuals exposed to potentially lethal doses of radiation is of paramount concern to health professionals and government agencies. We evaluated the efficacy of filgrastim to increase survival of nonhuman primates (NHP) exposed to an approximate mid-lethal dose (LD50/60) (7.50 Gy) of LINAC-derived photon radiation. Prior to total-body irradiation (TBI), nonhuman primates were randomized to either a control (n = 22) or filgrastim-treated (n = 24) cohorts. Filgrastim (10 μg/kg/d) was administered beginning 1 day after TBI and continued daily until the absolute neutrophil count (ANC) was >1,000/μL for 3 consecutive days. All nonhuman primates received medical management as per protocol. The primary end point was all cause overall mortality over the 60 day in-life study. Secondary end points included mean survival time of decedents and all hematologic-related parameters. Filgrastim significantly (P< 0.004) reduced 60 day overall mortality 20.8% (5/24) compared to the controls 59.1% (13/22). Filgrastim significantly decreased the duration of neutropenia, but did not affect the absolute neutrophil count nadir. Febrile neutropenia (ANC<500/μL and body temperature ≥103°F) was experienced by 90.9% (20/22) of controls compared to 79.2% (19/24) of filgrastim-treated animals (P = 0.418). Survival was significantly increased by 38.3% over controls. Filgrastim, administered at this dose and schedule, effectively mitigated the lethality of the hematopoietic subsyndrome of the acute radiation syndrome.

Original languageEnglish
Pages (from-to)89-100
Number of pages12
JournalRadiation Research
Volume179
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

primates
neutrophils
Primates
mortality
dosage
radiation
Neutrophils
body temperature
lethality
Whole-Body Irradiation
irradiation
schedules
Acute Radiation Syndrome
health
animals
Radiation
Government Agencies
Febrile Neutropenia
Mortality
Lethal Dose 50

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Biophysics
  • Radiation

Cite this

Farese, A. M., Cohen, M. V., Katz, B., Smith, C. P., Gibbs, A., Cohen, D. M., & MacVittie, T. J. (2013). Filgrastim improves survival in lethally irradiated nonhuman primates. Radiation Research, 179(1), 89-100. https://doi.org/10.1667/RR3049.1

Filgrastim improves survival in lethally irradiated nonhuman primates. / Farese, Ann M.; Cohen, Melanie V.; Katz, Barry; Smith, Cassandra P.; Gibbs, Allison; Cohen, Daniel M.; MacVittie, Thomas J.

In: Radiation Research, Vol. 179, No. 1, 01.2013, p. 89-100.

Research output: Contribution to journalArticle

Farese, AM, Cohen, MV, Katz, B, Smith, CP, Gibbs, A, Cohen, DM & MacVittie, TJ 2013, 'Filgrastim improves survival in lethally irradiated nonhuman primates', Radiation Research, vol. 179, no. 1, pp. 89-100. https://doi.org/10.1667/RR3049.1
Farese, Ann M. ; Cohen, Melanie V. ; Katz, Barry ; Smith, Cassandra P. ; Gibbs, Allison ; Cohen, Daniel M. ; MacVittie, Thomas J. / Filgrastim improves survival in lethally irradiated nonhuman primates. In: Radiation Research. 2013 ; Vol. 179, No. 1. pp. 89-100.
@article{20a18a3a64924fa4a5f45c8c12d23738,
title = "Filgrastim improves survival in lethally irradiated nonhuman primates",
abstract = "Treatment of individuals exposed to potentially lethal doses of radiation is of paramount concern to health professionals and government agencies. We evaluated the efficacy of filgrastim to increase survival of nonhuman primates (NHP) exposed to an approximate mid-lethal dose (LD50/60) (7.50 Gy) of LINAC-derived photon radiation. Prior to total-body irradiation (TBI), nonhuman primates were randomized to either a control (n = 22) or filgrastim-treated (n = 24) cohorts. Filgrastim (10 μg/kg/d) was administered beginning 1 day after TBI and continued daily until the absolute neutrophil count (ANC) was >1,000/μL for 3 consecutive days. All nonhuman primates received medical management as per protocol. The primary end point was all cause overall mortality over the 60 day in-life study. Secondary end points included mean survival time of decedents and all hematologic-related parameters. Filgrastim significantly (P< 0.004) reduced 60 day overall mortality 20.8{\%} (5/24) compared to the controls 59.1{\%} (13/22). Filgrastim significantly decreased the duration of neutropenia, but did not affect the absolute neutrophil count nadir. Febrile neutropenia (ANC<500/μL and body temperature ≥103°F) was experienced by 90.9{\%} (20/22) of controls compared to 79.2{\%} (19/24) of filgrastim-treated animals (P = 0.418). Survival was significantly increased by 38.3{\%} over controls. Filgrastim, administered at this dose and schedule, effectively mitigated the lethality of the hematopoietic subsyndrome of the acute radiation syndrome.",
author = "Farese, {Ann M.} and Cohen, {Melanie V.} and Barry Katz and Smith, {Cassandra P.} and Allison Gibbs and Cohen, {Daniel M.} and MacVittie, {Thomas J.}",
year = "2013",
month = "1",
doi = "10.1667/RR3049.1",
language = "English",
volume = "179",
pages = "89--100",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "1",

}

TY - JOUR

T1 - Filgrastim improves survival in lethally irradiated nonhuman primates

AU - Farese, Ann M.

AU - Cohen, Melanie V.

AU - Katz, Barry

AU - Smith, Cassandra P.

AU - Gibbs, Allison

AU - Cohen, Daniel M.

AU - MacVittie, Thomas J.

PY - 2013/1

Y1 - 2013/1

N2 - Treatment of individuals exposed to potentially lethal doses of radiation is of paramount concern to health professionals and government agencies. We evaluated the efficacy of filgrastim to increase survival of nonhuman primates (NHP) exposed to an approximate mid-lethal dose (LD50/60) (7.50 Gy) of LINAC-derived photon radiation. Prior to total-body irradiation (TBI), nonhuman primates were randomized to either a control (n = 22) or filgrastim-treated (n = 24) cohorts. Filgrastim (10 μg/kg/d) was administered beginning 1 day after TBI and continued daily until the absolute neutrophil count (ANC) was >1,000/μL for 3 consecutive days. All nonhuman primates received medical management as per protocol. The primary end point was all cause overall mortality over the 60 day in-life study. Secondary end points included mean survival time of decedents and all hematologic-related parameters. Filgrastim significantly (P< 0.004) reduced 60 day overall mortality 20.8% (5/24) compared to the controls 59.1% (13/22). Filgrastim significantly decreased the duration of neutropenia, but did not affect the absolute neutrophil count nadir. Febrile neutropenia (ANC<500/μL and body temperature ≥103°F) was experienced by 90.9% (20/22) of controls compared to 79.2% (19/24) of filgrastim-treated animals (P = 0.418). Survival was significantly increased by 38.3% over controls. Filgrastim, administered at this dose and schedule, effectively mitigated the lethality of the hematopoietic subsyndrome of the acute radiation syndrome.

AB - Treatment of individuals exposed to potentially lethal doses of radiation is of paramount concern to health professionals and government agencies. We evaluated the efficacy of filgrastim to increase survival of nonhuman primates (NHP) exposed to an approximate mid-lethal dose (LD50/60) (7.50 Gy) of LINAC-derived photon radiation. Prior to total-body irradiation (TBI), nonhuman primates were randomized to either a control (n = 22) or filgrastim-treated (n = 24) cohorts. Filgrastim (10 μg/kg/d) was administered beginning 1 day after TBI and continued daily until the absolute neutrophil count (ANC) was >1,000/μL for 3 consecutive days. All nonhuman primates received medical management as per protocol. The primary end point was all cause overall mortality over the 60 day in-life study. Secondary end points included mean survival time of decedents and all hematologic-related parameters. Filgrastim significantly (P< 0.004) reduced 60 day overall mortality 20.8% (5/24) compared to the controls 59.1% (13/22). Filgrastim significantly decreased the duration of neutropenia, but did not affect the absolute neutrophil count nadir. Febrile neutropenia (ANC<500/μL and body temperature ≥103°F) was experienced by 90.9% (20/22) of controls compared to 79.2% (19/24) of filgrastim-treated animals (P = 0.418). Survival was significantly increased by 38.3% over controls. Filgrastim, administered at this dose and schedule, effectively mitigated the lethality of the hematopoietic subsyndrome of the acute radiation syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84872104992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872104992&partnerID=8YFLogxK

U2 - 10.1667/RR3049.1

DO - 10.1667/RR3049.1

M3 - Article

VL - 179

SP - 89

EP - 100

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 1

ER -